Home > Journals > Esperienze Dermatologiche > Past Issues > Esperienze Dermatologiche 2020 March;22(1) > Esperienze Dermatologiche 2020 March;22(1):5-9



Publishing options
To subscribe
Submit an article
Recommend to your librarian


Publication history
Cite this article as


ORIGINAL ARTICLE   Free accessfree

Esperienze Dermatologiche 2020 March;22(1):5-9

DOI: 10.23736/S1128-9155.19.00495-3


language: English

Quercetin Phytosome reduces the wheal response to histamine injection

Gianni BELCARO 1, 2, 3 , Maria R. CESARONE 1, 2, 3, Claudia SCIPIONE 1, Valeria SCIPIONE 1, Mark DUGALL 1, 2, 3, Shu HU 1, 2, 3, Beatrice FERAGALLI 2, Morio HOSOI 1, Claudia MAIONE 1, Roberto COTELLESE 2, Paola DI ROCCO 1

1 Irvine3 Labs & San Valentino Vascular Screening Project, Chieti, Italy; 2 DSMO-Biotec, Outpatients Vascular Surgery, Chieti-Pescara University, Chieti, Italy; 3 International Agency for Pharma-Standard Supplements (IAPSS), Pescara, Italy


BACKGROUND: The objective of this registry was to evaluate the effect of supplementation with Quercetin Phytosome® (Quercefit™, QFit) on cutaneous histamine reaction model ‘Wheal and flare’ and on capillary permeability in healthy subjects.
METHODS: Supplemented subjects either consumed a full dose (500 mg/day) or a reduced dose (250 mg/day) of QFit for 3 days, before receiving a cutaneous micro-injection of histamine. After the injection, the wheal and redness areas on the skin were evaluated. Time until complete disappearance of flares and skin thickness were measured. Microcirculation (as laser Doppler flux) at the injection site was recorded. Capillary filtration (CF) in the lower limbs was measured by venous occlusion plethysmography. A comparable group did not take supplementation (control).
RESULTS: There were no safety problems. Compared with controls, the reaction to histamine was reduced in the groups supplemented with QFit. The higher dose was more effective. The wheal and the redness area were significantly smaller, and the skin thickness had a lower increase in microcirculation (flux). CF in supplemented subjects was also significantly lower after 3 days of QFit consumption, in comparison with controls.
CONCLUSIONS: In conclusion, this pilot evaluation indicates a dose-related, antihistaminic effect of QFit and its good safety profile. The reduced CF suggests a potential preventive role of QFit in subclinical and clinical conditions associated with altered histamine release and in edema prevention.

KEY WORDS: Histamine; Quercetin; Capillary permeability; Edema

top of page